Article Text

Download PDFPDF

Use of trastuzumab in the treatment of metastatic endometrial cancer
  1. E. Jewell*,
  2. A. A. Secord*,
  3. T. Brotherton and
  4. A. Berchuck*
  1. * Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina
  2. Danville Hematology Oncology, Danville, Virginia
  1. Address correspondence and reprint requests to: Elizabeth Jewell, MD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, P.O. Box 3616, Durham, NC 27710, USA. Email: jewel004{at}mc.duke.edu

Abstract

Systemic therapy of metastatic endometrial cancer is relatively ineffective. Response rates to chemotherapy and hormonal therapy in published studies range from 11% to 57%, but most responses are partial and of limited duration. In this case, we present a 76-year-old woman with stage IIIA endometrial adenocarcinoma who was initially treated with surgery and pelvic radiation. She developed multiple pulmonary metastases. She was treated with weekly paclitaxel chemotherapy. Immunostaining revealed that the primary endometrial cancer overexpressed HER-2/neu. Trastuzumab was added to the regimen, and a dramatic partial response was achieved. After a second pulmonary relapse following discontinuation of prior therapy, she was again successfully treated with trastuzumab in combination with paclitaxel and then docetaxel. Therefore, trastuzumab may be a useful adjuvant to taxane-based chemotherapy in some patients with metastatic endometrial cancers that overexpress HER-2/neu.

  • endometrial cancer
  • HER-2/neu
  • trastuzumab

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.